Fig. 1From: Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapyLaboratory test trends indicating hematologic toxicity. Points indicate median change compared to baseline. FU follow-upBack to article page